Dickmeyer Boyce Financial Management Inc. Makes New $1.04 Million Investment in Eli Lilly and Company $LLY

Dickmeyer Boyce Financial Management Inc. acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,132 shares of the company’s stock, valued at approximately $1,041,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new position in Eli Lilly and Company during the 4th quarter worth $12,976,634,000. J. Stern & Co. LLP grew its position in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after buying an additional 4,038,502 shares in the last quarter. Cardano Risk Management B.V. raised its position in shares of Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after buying an additional 2,131,734 shares in the last quarter. Fifth Third Bancorp lifted its stake in shares of Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Eli Lilly and Company by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after acquiring an additional 1,432,069 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide met its primary endpoints in two additional Phase 3 trials, with patients losing up to about 20.8% to 22.6% of body weight, strengthening the case for a highly valuable new obesity franchise. Reuters: Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
• Positive Sentiment: Lilly said it now plans to file for FDA approval in the first quarter of 2027, keeping the drug on track for a potential future launch even though the filing was pushed back. CNBC: Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
• Neutral Sentiment: Lilly is also expanding its pipeline through the acquisition of AtaiBeckley, a psychedelic medicine biotech, which could support longer-term diversification but is not an immediate earnings driver. Motley Fool: Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here’s What You Need to Know.
• Negative Sentiment: The FDA filing for retatrutide was delayed from an earlier timeline, and Lilly said it needs more manufacturing and quality-control data, which adds a modest regulatory timing risk. Yahoo Finance: Lilly to file for next-gen obesity drug approval in early 2027
• Negative Sentiment: Novo Nordisk has filed a lawsuit accusing Lilly of misleading weight-loss advertising, creating headline legal risk in the competitive obesity-drug market. Yahoo Finance: How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story

Analysts Set New Price Targets

LLY has been the topic of a number of research reports. The Goldman Sachs Group reissued a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a report on Thursday, May 21st. Bank of America raised their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, Guggenheim upped their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,185.31 on Friday. The firm has a 50 day simple moving average of $1,132.74 and a 200 day simple moving average of $1,039.05. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The stock has a market cap of $1.12 trillion, a P/E ratio of 42.11, a P/E/G ratio of 1.47 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the business posted $3.34 EPS. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 34.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.